EXPRESS MAIL NO.: <u>EL 451 600 441 US</u>

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Dasseux, et al.

Confirmation No.: 9219 Application No.: 09/465,718

Group Art Unit: 1631 Filed: December 17, 1999

Examiner: Borin, M.

APOLIPOPROTEIN A-I AGONISTS Attorney Docket No.: 9196-018-999

AND THEIR USE TO TREAT

DYSLIPIDEMIC DISORDERS

TERMINAL DISCLAIMER FEE SHEET

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

The fee for processing the attached Terminal Disclaimer is believed to be \$110.00. Please charge the required fee and any other necessary fees, fees under 37 C.F.R. §1.17 and all required extension of time fees, or credit any overpayment, to Pennie & Edmonds LLP, U.S. Deposit Account No. 16-1150 (Order No. 9196-018-999). A copy of this sheet is enclosed for accounting purposes.

Respectfully submitted,

Date: June 11, 2003

> Rahul Pathak 42,983 (Reg. No.)

For Laura A. Coruzzi (Reg. No. 30,742)

PENNIE & EDMONDS LLP 1155 Avenue of the Americas

New York, New York 10036-2711 (212) 790-9090

USSN: 09/465,718 CA1: 338538.1



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Dasseux, et al.

Confirmation No.: 9219

Application No.: 09/465,718

Group Art Unit: 1631

Filed: December 17, 1999

Examiner: Borin, M.

For: APOLIPOPROTEIN A-I AGONISTS

Attorney Docket No.: 9196-018-999

AND THEIR USE TO TREAT

DYSLIPIDEMIC DISORDERS

TERMINAL DISCLAIMER

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Jean-Louis Dasseux, Renate Sekul, Klaus Büttner, Isabelle Cornut, Günther Metz, and Jean Dufourcq (hereinafter "Owners"), represent that they are the owners of the above identified application and of U.S. Application No. 09/453,833.

The Owners hereby disclaim the terminal part of any patent granted on the present application which would extend beyond the expiration date of U.S. Application No.

The Owners hereby agree that the above identified application shall be enforceable only for and during such period that the legal title to the corresponding patent shall be the same as the legal title to U.S. Application No. 09/453,833. This agreement is to run with any patent granted on the above identified application and is to be binding upon the grantee, its successors, and assigns.

In making the above disclaimer, the Inventors do not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 to 156 and 173, as presenting the booms 161150 terminal disclaimer, of U.S. Application Nos. 09/453,833 in the event that said patent tates: 09465718 expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. 1.321, has all claims canceled by a reexamination certificate, is reissued, or is

otherwise terminated prior to the expiration of its full statutory term, except for the separation of legal title stated above.

The Commissioner is hereby authorized to charge the Statutory Disclaimer fee of \$110.00 required pursuant to 37 C.F.R.1.20(d) and any other fee associated with the filing of this document to Pennie & Edmonds LLP Deposit Account No. 16-1150 (Order No. 9196-018-999). The undersigned is an attorney of record.

Respectfully submitted,

Date: June 11, 2003

Francis E. Morris

PENNIE & EDMONDS, LLP

3300 Hillview Avenue Palo Alto, CA 94304 (650) 493-4935

TO EXAMINER: M. Borin MOSE MONTGOMERY ROOM (1E/8) AFTER FINAL YES NO NUMBER OF THE MILE OF THE PROPERTY OF THE PR	
AFTER FINAL ART UNIT: 1631	
AFTER FINAL VEG	
INSTRUCTIONS NO AUTON	
approplate form paragraphs identified by this informal memo in your next office action to notify applicant about the T.D. If SHOULD A COPY BE IN LEFT IN FILE. appropriate form paragraphs identified by this informal memo in your next office action to notify applicant about the Examiner. THIS MEMO IS AN INFORMAL, INTERNAL MEMO ONLY. IT MUST NOT BE MAN TO TO US SPECIAL PROOF.	you am OR
The F.D. is PROPER and has been recorded. (See 14.23). [1] The T.D. is NOT PROPER and has not been accepted for the reason(s) checked below. (See 14.24). [2] The recording fee of \$	
1 The reason's) checked by	
(See 14.26.07)	
	arge
[] The T.D. does not satisfy Rule 321(b)(3) in that the person who has signed the T.D. has not stated his/her interest 14.26.01).	
14.26.01).	•
(and/or the extent of the Interest of the business entity represented by the signature) in the application/patent. (See 14.26 and Rule 321(c). (See 14.27, 14.27.01). [] The T.D. lacks the enforceable only during the common owership clause needed to overcome a double patenting rejection of the certific to a particular claims(s) which the second of the certific to a particular claims(s) which the second of the certific to a particular claims(s) which the second of the certific to a particular claims(s) which the second of the certific to a particular claims(s) which the second of the certific to a particular claims(s) which the second of the certific to the cert	ď
(C). (See 14.27, 14.27.01).	
[] It is directed to a particular claims(s), which is not acceptable since "the disclaimer must be of a terminal portion of the [] The person who signed the terminal disclaim.	n, ·
has falled to state his/her capacity to sign for the business entity (\$20.44.00) s not recognized as an officer of the business entity (\$20.44.00)	
and frame specified as to where such evidence is recorded in the office. 37 CFR 3.73(b). (See 14.30).	
knowledge and belief the title is in the assigned and the substitute of the state of the substitute of	
1 1 Attorney not of record in oath/decl or a second state of the owners.	
[] Attorney not of record in oath/decl. or a seperate paper filed appointing a new or associate attorney. (See 14.29.01). [] The serial number of the application (or the number of the patent) which forms the basis for the double patenting is	
[] The serial number of this application (or the number of the patent in reexam or reissue case(s) being disclaimed is missing [] The period disclaimed is incorrect or not specified.	
of incorrect. (See 14.26, 14.26,04 or 14 or the number of the patent in regram or reliable to the control of the patent in regram or reliable to the control of the patent in regram or reliable to the control of the patent in regram or reliable to the control of the patent in regram or reliable to the control of the patent in regram or reliable to the control of the patent in regram or reliable to the regram or reliable to the patent in regram or reliable to the regram or reliable to th	
[] The period disclaimed is incorrect or not specified (See 14.27 case)	
[] The period disclaimed is incorrect or not specified. (See 14.27, 14.27.2 or 14.27.3)(For Samples 14.27.04 and 14.27.05)	
Suggestion to request refund of \$ (See 14.35, 14.36).	
MAY BE FAXED IN TO THE GROUP	
TOUR DISCUSSION OF THE PROPERTY OF THE PROPERT	
[] Sample of a TD over a pending application and assignee Certificate (See 14.37). [] Sample Assignee Certificate under 37 CFR 3.73 (b) (See 14.38).	